Patiënteninformatiedag preeclampsie en HELLP
IN LIJN MET DE MAATREGELEN VAN HET RIVM RONDOM COVID-19 WORDT DE PATIËNTENDAG UITGESTELD TOT NADER ORDER. MEER INFORMATIE VOLGT.
Samen met Hart voor HELLP organiseert de afdeling Obstetrie van het MUMC+ op zaterdag 23 mei 2020 een patiënteninformatiedag voor vrouwen die preeclampsie of HELLP hebben doorgemaakt.
Tijdens deze middag wordt er aandacht besteed aan de lichamelijke en psychische nasleep van preeclampsie en HELLP. Er zijn diverse lezingen en er is de mogelijkheid om vragen te stellen en/of ervaringen te delen (wanneer gewenst).
Interesse? Graag verwelkomen we u en eventueel uw partner of een naaste op 23 mei in het MUMC+. Aanmelden kan via firstname.lastname@example.org.
Vascular pregnancy disorders complicate 10% of all pregnancies and are responsible for 50.000 maternal deaths annually. These complication include fetal growth restriction, pregnancy induced hypertension and preeclampsia (PE). PE is clinically defined as de novo hypertension along with end-organ disease after 20 weeks of gestation. Unfortunately, the exact etiology of PE is not completely unraveled but PE is thought to be an endothelial disease superimposed upon pre-existing circulatory, metabolic and inflammatory abnormalities which is exposed (or luxated) during pregnancy when defective placentation occurs. On the short term PE is associated with serious fetal (small for gestational age infancy, fetal death and preterm birth) and maternal complications (pulmonary edema, stroke, acute respiratory distress syndrome, placental abruption, HELLP (Hemolysis, Elevated Liver enzymes, and Low Platelets) syndrome, disseminated intravascular coagulation, acute renal failure, liver rupture, seizures, or death. On the long term, PE is associated with increased long-term cardiovascular risk including ischemic heart disease, cerebrovascular accidents, arrhythmias, heart failure and diastolic dysfunction. The past decennium, many studies on the association between PE and the risk on CVD have emerged. However, research is still needed to predict PE, to study the link between CV risk factors and PE and to predict more precisely which women will develop CVD after complicated pregnancies.
Although the Queen of Hearts study initially started as a large consortium study, aiming to detect early stages of heart failure in women, it developed quickly and became a large research line, including several studies with two major objectives being: reducing cardiovascular disease and hypertensive pregnancy disorders (small for gestational age infancies, preeclampsia, HELLP-Syndrome) with 25% the next 25 years.
Objective 1: To decrease the risk on cardiovascular disease in women with 25% the next 25 years. This can only be achieved if we recognize pregnancy as a women- specific biological stresstest. Nowadays, one out of 4 women dies due to cardiovascular disease. Queen of Hearts researchers are developing early detection tools to assess which women are at increased risk for cardiovascular disease early in life to assure early preventive measures, before the disease evolves. The pregnancy is used as an important risk indicator.
Objective 2: To decrease the risk of hypertensive pregnancy disorders with 25% the next 25 years. Hypertensive pregnancy disorders (small for gestational age babies, preeclampsia, HELLP-Syndrome) are the major causes of maternal and fetal morbidity and mortality. Every year, 76.000 women and 500.000 babies die due to this disease. Queen of Hearts researchers are working on studies for early detection and prevention of hypertensive pregnancy disorders.